Novo Nordisk A/S’ NVO Canada unit on Thursday introduced that Well being Canada has accepted for overview, below the Precedence Evaluation coverage, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly remedy for individuals dwelling with MASH (metabolic dysfunction-associated steatohepatitis).
“Semaglutide 2.4 mg represents a therapeutic development for sufferers dwelling with MASH, addressing a important unmet medical want,” says Vince Lamanna, President of Novo Nordisk Canada Inc. “Well being Canada’s acceptance of the Semaglutide 2.4 mg submission for overview brings us one step nearer to offering the primary remedy choice for eligible individuals dwelling with MASH.”
Additionally Learn: Eli Lilly Positioned To Dominate Weight problems Market With Oral Choice, Analyst Initiates With Confidence
In November 2024, Well being Canada authorized Wegovy (semaglutide injection) to scale back the chance of non-fatal myocardial infarction (MI) in adults with established heart problems and a BMI equal to or better than 27 kg/m2.
It was the primary Well being Canada-approved remedy to help each persistent weight administration and to cut back the chance of non-fatal MI.
MASH is a persistent, progressive metabolic illness affecting the liver.
Amongst people who find themselves obese or have weight problems, about one in three even have MASH.
Extra fats can construct up within the liver, which, over time, can result in irritation and extreme scarring of the liver.
By 2030, the prevalence of MASH within the Canadian normal inhabitants is estimated to extend from 5.2% to six.5%.
In Canada, the variety of deaths is predicted to double in individuals dwelling with MASH by 2030.
On Thursday, Novo Nordisk introduced that CVS Well being Inc’s CVS CVS Caremark, a Pharmacy Profit Supervisor (PBM), determined that Wegovy (semaglutide) injection 2.4 mg will quickly be the popular GLP-1 medication on its largest industrial template formularies.
This transformation will take impact on July 1, 2025.
In February, the FDA confirmed that every one doses of Wegovy have been accessible. In March, Novo Nordisk launched NovoCare Pharmacy to supply direct-to-patient, handy house shipments of all Wegovy dose strengths at a decreased value of $499 per 30 days for self-paying sufferers.
Extra lately, the Wegovy financial savings supply was up to date, permitting eligible self-paying sufferers to get the $499-per-month value at their native pharmacy.
On Tuesday, Novo Nordisk and Hims & Hers Well being, Inc. HIMS introduced a long-term collaboration.
The corporate mentioned that people could also be prescribed Wegovy at a single, unified value beginning at $599 per 30 days. The providing is on the market this week on the Hims & Hers platform.
This new providing builds on Hims & Hers’ current suite of weight reduction options and gives self-pay sufferers with entry to all dose strengths of Wegovy in a high-quality pen.
Value Motion: NVO inventory is up 5.5% at $69.21at final examine Friday.
Learn Subsequent:
Picture: Shutterstock
